GLP-1 Receptor Agonist Therapy for Glucocorticoid-Induced Dysglycaemia: A Systematic Review

Related

• Diabetes, Obesity & Metabolism·4 Oct 2026

  GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

• Diabetes & Vascular Disease Research·4 Oct 2026

  SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

• Nature Medicine·4 Oct 2026

  Semaglutide may protect kidneys by reducing vascular resistance

  

• Clinical Journal of the American Society of Nephrology·4 Oct 2026

  SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes